How GLP-1 medicines work for weight loss

How the signal works

GLP-1 stands for glucagon-like peptide-1. It is a hormone involved in appetite and food intake. A receptor is a part of a cell that receives a signal. Semaglutide activates the GLP-1 receptor. Tirzepatide activates this receptor and a second one called GIP. GIP stands for glucose-dependent insulinotropic polypeptide, another hormone involved in metabolic signals.

The labels describe effects on brain regions involved in appetite. Their direct evidence of nerve-cell activation comes from studies in animals. Trials in people provide a different kind of evidence: reported hunger and the amount people eat.

What studies measured in people

A 20-week trial enrolled 72 adults with obesity. One group received injected semaglutide, raised to 2.4 mg once a week. The other group received a treatment with no active medicine (placebo). At a test lunch, the semaglutide group ate 35% fewer calories than the placebo group. They also reported less hunger and more fullness.

That result applies to one measured meal under study conditions. The trial did not show that everyone eats 35% less each day.

A later trial followed 120 adults with overweight or obesity for 60 weeks. It compared semaglutide 2.4 mg with placebo. The semaglutide group had larger reductions in calories eaten at test lunches at weeks 20, 40, and 60. Differences in reported appetite were no longer statistically significant at weeks 40 and 60.

Reported hunger and measured food intake can change differently. These group results cannot determine whether a medicine is working for an individual. The 60-week report also lists author relationships with drug companies.

Slower stomach emptying is part of the explanation

Food moving from the stomach into the small intestine is called gastric emptying. The semaglutide label says the medicine delays this process. For tirzepatide, the label says the delay is largest after the first dose and decreases over time.

The 20-week trial checked for delayed emptying with an indirect test. It tracked how fast the body absorbed paracetamol. At the final check, the test found no evidence of delayed emptying. That finding is limited to one method at one time point. The label warning about delayed emptying still applies.

Both product labels warn about stomach and bowel side effects that can be severe. Slower emptying does not establish that treatment is safe.

Effects on blood sugar are separate

Semaglutide and tirzepatide also affect insulin and glucagon, hormones involved in blood sugar control. Their labels describe insulin release that depends on glucose levels and reduced glucagon release.

Those effects do not make the products interchangeable. A mechanism cannot settle which product, if any, suits a person.

Follow the evidence from signal to meal

The product labels describe receptor activity and effects on appetite and stomach emptying. Those are mechanism statements. The semaglutide meal trials ask a different question: how much food did participants eat at a measured lunch, and how did they report hunger? A mechanism can help explain a trial result, but it cannot replace that result. Keep the receptor, the measured meal, and the person's long-term weight as separate steps in the explanation.

The 20-week study compared a semaglutide group with a placebo group under a defined test-meal procedure. Its 35% difference concerns calories at that lunch. It is a group comparison, not a daily allowance or a prediction for one person. A reader who sees the number without the words 'test lunch' may wrongly carry it into every meal and every week. The trial did not measure such a universal reduction.

The later 60-week study adds time. It reports lower test-meal intake at weeks 20, 40, and 60, while differences in appetite ratings were no longer statistically significant at the later checks. This does not mean the two results conflict. A person's reported feeling and the amount eaten at one test meal are distinct measures. The later trial makes that distinction visible, but it still cannot predict an individual response.

Why one stomach-emptying result needs context

The Wegovy label describes delayed gastric emptying. The 20-week semaglutide trial used paracetamol absorption as an indirect test and found no evidence of a delay at its final check. The two statements answer different questions. A product label describes a known effect and its risk context. One indirect test at one time point measures a narrower condition. It cannot cancel every label warning or show that the process never changes during treatment.

The Zepbound label says the delay with tirzepatide is greatest after the first dose and diminishes over time. That time pattern is another reason to specify when a measurement occurred. It does not make the two medicines identical, and it is not a way to choose between them. A comparison should use each product's own label and measured evidence rather than transfer a result from one compound to another.

Stomach emptying is only one part of this explanation. The labels also describe appetite and blood-sugar effects, while human studies measure eating behavior. No single pathway gives a complete forecast of weight change or adverse effects. When a headline attributes all weight loss to 'food staying in the stomach,' check whether its source actually tested that account against other mechanisms.

Match the product to the claim

GLP-1 is a hormone name, a receptor name in common discussion, and shorthand for a group of medicines. Those uses are related but not interchangeable. Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at GLP-1 and GIP receptors. A result from one semaglutide trial does not establish the size or safety of an effect for tirzepatide. State the exact molecule before quoting a number.

The FDA warns that unapproved GLP-1 products have not received its review for safety, effectiveness, and quality. A website can use a familiar molecule name while discussing a different active ingredient or a different finished product. A mechanism paragraph cannot bridge that gap. The safe reading task is to identify the precise product in the label or paper and leave other products outside that result.

What this explanation cannot tell you

Weight-management medicines differ in their uses, benefits, and risks. A clinician considers health conditions and other medicines when assessing treatment. The mechanism alone does not provide that assessment.

The exact product matters as well. The FDA says unapproved GLP-1 products do not undergo its review for safety, effectiveness, and quality. It also identifies semaglutide sodium and acetate as different active ingredients from those in approved products. A familiar ingredient name does not establish equivalence.